Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment
- PMID: 9704727
- DOI: 10.1200/JCO.1998.16.8.2745
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment
Abstract
Purpose: Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study was to determine the pathophysiology of CPT-11-induced delayed-onset diarrhea and assess the efficacy of combined antidiarrheal medication in a phase II, prospective, successive-cohorts, open study.
Patients and methods: Twenty-eight patients with advanced colorectal cancer refractory to fluorouracil (5-FU) therapy received CPT-11 350 mg/m2 every 3 weeks. The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily. Before treatment, and if late diarrhea occurred, patients underwent colon mucosal biopsies for CPT-11 and topoisomerase I levels; intestinal transit time; fecalogram; fat and protein excretion; alpha1-antitrypsin clearance; D-xylose test; blood levels for vasoactive intestinal polypeptide, glucagon, gastrin, somatostatin, prostaglandin E2, and carboxylesterase; CPT-11/SN-38 and SN-38 glucuronide pharmacokinetics; and stool cultures.
Results: Delayed-onset diarrhea occurred during the first three treatment cycles in 23 patients (82%). Electrolyte fecal measurements showed a negative or small osmotic gap in nine of nine patients and an increased alpha1-antitrypsin clearance in six of six patients. There were no modifications in stool cultures or hormonal dysfunction. Four of 11 patients (36%) with delayed-onset diarrhea in the first cohort responded to acetorphan, whereas nine of 10 patients (90%) responded to the combination of acetorphan and loperamide (P < .02).
Conclusion: CPT-11-induced delayed-onset diarrhea is caused by a secretory mechanism with an exudative component. Early combined treatment with loperamide and acetorphan seems effective in controlling the diarrheal episodes.
Similar articles
-
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.J Clin Oncol. 1996 Apr;14(4):1128-35. doi: 10.1200/JCO.1996.14.4.1128. J Clin Oncol. 1996. PMID: 8648367 Clinical Trial.
-
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.Br J Cancer. 2000 Aug;83(4):431-7. doi: 10.1054/bjoc.2000.1303. Br J Cancer. 2000. PMID: 10945486 Free PMC article. Clinical Trial.
-
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.J Clin Oncol. 1995 Jan;13(1):210-21. doi: 10.1200/JCO.1995.13.1.210. J Clin Oncol. 1995. PMID: 7799022 Clinical Trial.
-
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.Eur J Cancer. 1996;32A Suppl 3:S18-23. doi: 10.1016/0959-8049(96)00293-6. Eur J Cancer. 1996. PMID: 8943661 Review.
-
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.Semin Oncol. 1996 Feb;23(1 Suppl 3):34-41. Semin Oncol. 1996. PMID: 8633252 Review.
Cited by
-
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.Curr Oncol. 2007 Feb;14(1):13-20. doi: 10.3747/co.2007.96. Curr Oncol. 2007. PMID: 17576459 Free PMC article.
-
Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.Invest New Drugs. 2001;19(4):341-3. doi: 10.1023/a:1010678214152. Invest New Drugs. 2001. PMID: 11561696
-
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.Invest New Drugs. 2014 Dec;32(6):1071-82. doi: 10.1007/s10637-014-0138-x. Epub 2014 Jul 27. Invest New Drugs. 2014. PMID: 25064374 Free PMC article.
-
Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity.Mol Pharmacol. 2013 Aug;84(2):208-17. doi: 10.1124/mol.113.085852. Epub 2013 May 20. Mol Pharmacol. 2013. PMID: 23690068 Free PMC article.
-
A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea.Healthcare (Basel). 2022 Jan 24;10(2):218. doi: 10.3390/healthcare10020218. Healthcare (Basel). 2022. PMID: 35206833 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous